Bengaluru, India — BrainSight AI, a deep-tech neuroscience startup, has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, and existing investors. The company, which previously secured $925,000 in funding from Pfizer and others, plans to utilize the fresh investment to expand its footprint and enhance its AI-driven R&D capabilities.
Founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSight AI leverages artificial intelligence to advance precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric disorders. The company’s AI-powered platform integrates neuroscience and machine learning to accelerate patient outcomes.
BrainSight AI’s flagship products include Voxelbox, a platform that offers clinicians access to functional MRI (fMRI) processing and machine-learning models, and Snowdrop, a patient care app designed to enhance treatment compliance and build detailed patient profiles. By mapping macro-scale neural connections in the brain, BrainSight AI enables clinicians to better understand the correlation between brain physiology and function for accurate diagnosis and prognosis.
Currently collaborating with over 40 leading hospitals across India, particularly in neurosurgery and radiology, BrainSight AI has focused on brain tumor cases. The company plans to extend its solutions to neurological and psychiatric disorders, while expanding operations to Africa, Southeast Asia, the US, and other markets, including Tier I and Tier II cities in India.
A spokesperson noted, “BrainSight AI is committed to transforming brain care through AI, paving the way for innovative solutions in neuroscience.”
This funding marks a significant milestone for the company as it continues to innovate at the intersection of AI and neuroscience.
